The SELECT trial with the GLP-1RA semaglutide met its primary endpoint. Semaglutide as adjunct to standard of care reduced the risk of the composite endpoint of CV death, nonfatal MI or nonfatal stroke (3-component MACE) up to five years compared with placebo.

Semaglutide treatment at a dose of 2.4 mg reduced the risk of 3-component MACE by 20% in adults with overweight or obesity and established CVD compared with placebo. A similar safety and tolerance profile of semaglutide 2.4 mg was observed as previously reported in other trials with semaglutide 2.4 mg.

The SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity) trial was a multi-center, randomized, double-blind, parallel-group, placebo-controlled trial with 17,604 adults (≥45 years old) with overweight or obesity (BMI ≥27 kg/m²) and established CVD with no prior history of diabetes. Participants received subcutaneous once-weekly semaglutide 2.4 mg or placebo, as adjunct to standard of care. The primary endpoint was the occurrence of first MACE, which included CV death, nonfatal MI or nonfatal stroke. A total of 1,270 first MACEs were reported. Key secondary endpoints included mortality, CV risk factors, glucose metabolism, body weight, and renal function.

The results of SELECT will be presented at a scientific conference later this year.

Source: Novo Nordisk, August 8, 2023